SCHEMBL6895065

SCHEMBL6895065

CCCCCc1cc(O)c2c3c(C(=O)OC)cccc3n(Cc3ccccc3F)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90B1 P14625 1/20 0.37
CNR2 P34972 2/20 0.36
THRB P10828 2/20 0.36
POLB P06746 1/20 0.36
FGFR1 P11362 1/20 0.36
FGFR4 P22455 1/20 0.36
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
AGTR1 P30556 1/20 0.35
AGTR2 P50052 1/20 0.35
TP53 P04637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6892764 0.91 LMNA (0.44) LMNAL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL6897067 0.90 CNR1 (0.41) LMNAL3MBTL1KDM4EALDH1A1KMT2A
SCHEMBL6782670 0.90 ALDH1A1 (0.39) LMNAL3MBTL1KDM4EALDH1A1RAB9A
SCHEMBL6892057 0.89 HSP90AA1 (0.37) KDM4EALDH1A1KMT2AMEN1HSP90AA1
SCHEMBL6895127 0.89 CNR1 (0.42) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL5212605 0.89 MAPK8 (0.42) ALDH1A1THRBAGTR1AGTR2MAPT
SCHEMBL6894818 0.89 HSP90AA1 (0.39) KDM4EALDH1A1KMT2AMEN1HSP90AA1
SCHEMBL6894406 0.88 MAPK8 (0.42) KDM4EALDH1A1KMT2AMEN1CNR2
SCHEMBL6896241 0.88 CNR1 (0.42) KDM4EALDH1A1KMT2AMEN1HSP90AA1
SCHEMBL6893816 0.88 PLA2G2A (0.42) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed